Menu
/REGISTER
Montecito
Nixon Peabody
Chase
Bank of America
Loading...
You are here:  Home  >  Biotech  >  Current Article

MannKind revenue grows but so does net loss

By   /   Tuesday, February 25th, 2020  /   Comments Off on MannKind revenue grows but so does net loss

    Print       Email
Revenue continued to climb for MannKind’s inhalable insulin product Afrezza, gaining 35 percent in the fourth quarter to $7.8 million, but net loss rose 46 percent to $14 million during the period. Overall in 2019, the Westlake Village biotech grew sales of Afrezza 46 percent to $25.6 million, slimming net losses by 40 percent to…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Movegreen makes LA, Orange County acquisitions

Read More →